CRIS Current Research Information System

AZZAROLI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.144
EU - Europa 5.144
AS - Asia 2.565
AF - Africa 314
SA - Sud America 18
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 1
Totale 15.194
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.124
GB - Regno Unito 1.340
IT - Italia 993
CN - Cina 862
SE - Svezia 738
SG - Singapore 734
DE - Germania 657
VN - Vietnam 488
UA - Ucraina 324
IN - India 309
IE - Irlanda 261
RU - Federazione Russa 195
FR - Francia 188
EE - Estonia 106
ZA - Sudafrica 97
CH - Svizzera 95
TG - Togo 93
BG - Bulgaria 66
NG - Nigeria 46
FI - Finlandia 44
CI - Costa d'Avorio 43
JO - Giordania 38
GR - Grecia 29
SC - Seychelles 27
NL - Olanda 22
BE - Belgio 21
IR - Iran 20
PL - Polonia 20
CA - Canada 19
JP - Giappone 18
ID - Indonesia 15
PK - Pakistan 14
KR - Corea 13
SA - Arabia Saudita 11
AT - Austria 8
CZ - Repubblica Ceca 8
AU - Australia 7
BR - Brasile 7
HK - Hong Kong 7
HR - Croazia 7
EC - Ecuador 6
TR - Turchia 6
DK - Danimarca 5
EG - Egitto 5
ES - Italia 5
LB - Libano 5
MK - Macedonia 5
PH - Filippine 4
TH - Thailandia 4
IL - Israele 3
IQ - Iraq 3
AR - Argentina 2
BD - Bangladesh 2
NO - Norvegia 2
RO - Romania 2
RS - Serbia 2
UZ - Uzbekistan 2
AE - Emirati Arabi Uniti 1
CL - Cile 1
DZ - Algeria 1
EU - Europa 1
GL - Groenlandia 1
KG - Kirghizistan 1
KW - Kuwait 1
LK - Sri Lanka 1
MM - Myanmar 1
NZ - Nuova Zelanda 1
OM - Oman 1
PE - Perù 1
PT - Portogallo 1
SY - Repubblica araba siriana 1
TN - Tunisia 1
UG - Uganda 1
VE - Venezuela 1
Totale 15.194
Salva come PNG Salva come JPEG
Città #
Southend 1.229
Fairfield 1.180
Chandler 732
Singapore 657
Ashburn 474
Santa Clara 382
Wilmington 322
Princeton 308
Seattle 300
Woodbridge 300
Houston 297
Dublin 261
Dong Ket 258
Cambridge 225
Boardman 223
Jacksonville 203
Bologna 201
Ann Arbor 188
Westminster 118
Nanjing 111
Padova 95
Lomé 93
Berlin 91
Bern 82
New York 75
Medford 74
Saint Petersburg 72
Milan 62
Sofia 61
Dearborn 57
Jinan 57
Shenyang 47
Abeokuta 45
Hebei 45
Abidjan 43
San Diego 42
Beijing 41
Amman 38
Florence 37
Helsinki 36
Bremen 35
Des Moines 35
Nanchang 35
Turin 35
Mülheim 34
Rome 34
Changsha 33
Frankfurt am Main 33
Redmond 33
Shanghai 31
Guangzhou 24
Mahé 24
Redwood City 23
Jiaxing 22
Mountain View 22
Pune 22
Hangzhou 20
Tianjin 20
Olalla 19
Taizhou 19
Brussels 18
Norwalk 15
Tokyo 15
Zhengzhou 15
Bari 14
Jakarta 14
Los Angeles 14
Falls Church 13
Haikou 13
Kunming 12
Lanzhou 12
Ningbo 12
Verona 12
Washington 12
London 11
Shenzhen 11
Torino 11
Catania 10
Chengdu 10
Monmouth Junction 10
Casalecchio di Reno 9
Falkenstein 9
Leawood 9
Moscow 9
Napoli 9
Phoenix 9
Riyadh 9
Wuhan 9
Forlì 8
Kyiv 8
Lappeenranta 8
Paris 8
San Francisco 8
Xi'an 8
Bühl 7
Groningen 7
Harbin 7
Hong Kong 7
Lahore 7
Lübeck 7
Totale 10.131
Salva come PNG Salva come JPEG
Nome #
Chronic non allergic rhinitis with neutrophilis (NARNE) and gastroesophageal reflux disease (GERD): A possible correlation? 261
A new model for portal protein profile analysis in course of ileal intraluminal bile acid infusion using an in situ perfused rat intestine. 251
A statistical model predicting high hepatocyte proliferation index and the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis 219
G-CSF in Peg-IFN induced neutropenia in liver transplanted patients with HCV recurrence 187
Clinical trial: modulation of human placental multidrug resistance proteins in cholestasis of pregnancy by ursodeoxycholic acid. 184
Intrahepatic Cholestasis of Pregnancy: mRNAs for LIPF and ELOVL4 Genes Are Not Detectable in Circulating Maternal Plasma. 177
A RETROSPECTIVE STUDY ON INTRAHEPATIC CHOLESTASIS OF PREGNANCY: MARKERS OF PREMATURE DELIVERY 175
Clinical efficacy and effectiveness of ursodeoxycholic acid in cholestatic liver diseases. 172
The future of dual therapy for hepatitis C virus 166
Correlazione materno-fetale degli acidi biliari in corso di colestasi gravidica 162
Adverse effects of proton pump inhibitors. 161
Complete Remission of Advanced Hepatocellular Carcinoma Treated with Sorafenib and Concomitant Appearance of IgG4- related Diseases. A Case Report 154
High Doses of Ursodeoxycholic Acid Up-Regulate the Expression of Placental Breast Cancer Resistance Protein in Patients Affected by Intrahepatic Cholestasis of Pregnancy 153
Relationship between indocyanine green retention test, decompensation and survival in patients with Child-Pugh A cirrhosis and portal hypertension 149
Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study 148
Generation of a novel antibody probe to the Apical Sodium-Dependent Bile Acid Transporter that inhibits ileal bile acid absorption 144
Alisporivir for the treatment of chronic HCV 144
G-CSF administration is not related to Peg-IFN alfa-2b treatment duration nor response in liver transplanted patients with HCV recurrence. 141
Severe esophagitis in a patient with gastrointestinal stromal tumor treated with imatinib. 140
Interferon plus ribavirin and interferon alone in preventing hepatocellular carcinoma: a prospective study on patients with HCV related cirrhosis. 139
Monofocal hepatocellular carcinoma: How much does size matter? 137
CMV infection and biliary tract complications are related with a poor outcome of liver transplantation for HCV-related cirrhosis 134
The impact of assisted reproductive technology and chorionicity in twin pregnancies complicated by obstetric cholestasis 133
Recalibrating survival prediction among patients receiving trans‐arterial chemoembolization for hepatocellular carcinoma 132
Chronic NSAIDs Therapy and Upper Gastrointestinal Tract – Mechanism of Injury, Mucosal Defense, Risk Factors for Complication Development and Clinical Management 131
Severe immune thrombocytopenia after peg-interferonalpha2a, ribavirin and telaprevir treatment completion: A case report and systematic review of literature 131
Higher doses of peginterferon alpha-2b administered twice weekly improve sustained virological response in difficult-to-treat patients with chronic hepatitis C: results of a pilot randomized study 130
IL28 polymorphism and HCC after DAAs for chronic hepatitis C 127
Correlation between Indocyanine green retention test and esophageal varices among patients with hepatocellular carcinoma 126
The changing scenario of hepatocellular carcinoma in Italy: an update 126
An unusual cause of weight loss in a young Caucasian man 125
Mathematical model predicting high hepatocyte proliferation index and risk of HCC in patients with HCV related cirrhosis: a proposal for clinical validation 124
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score 123
Indocyanine green as a predictor of clinically significant portal hypertension in a prospective cohort study of patients with chronic liver disease 122
Spleen stiffness mirrors changes in portal hypertension after successful interferon-free therapy in chronic-hepatitis C virus patients 120
Regolazione dei trasportatori placentari degli acidi biliari MRP2, MRP3, MRP4 da parte dell’acido ursodesossicolico in corso di colestasi gravidica 117
Terapia cellulare in Epatologia 115
Spleen stiffness decrease as mirror of portal hypertension changes after successful interferon-free therapy in chronic-HCV patients 115
Ductal stones recurrence after extracorporeal shock wave lithotripsy for difficult common bile duct stones: Predictive factors 114
Proton pump inhibitors in cirrhosis: tradition or evidence based practice? 113
Size and location of spontaneous portosystemic shunts predict the risk of decompensation in cirrhotic patients 113
G-CSF administration is not related to PEG-IFN alfa-213 treatment duration nor response in liver transplanted patients with HCV recurrence 112
Noninvasive diagnosis of portal hypertension and esophageal varices through the identification of liver blood flow markers 112
Indocyanine green as a predictor of clinically significant portal hypertension in a prospective cohort study of patients with chronic liver disease. 111
Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment 111
Pharmacological modulation of MRP2 in primary biliary cirrhosis 110
P.09.6 IL28 POLYMORPHISM AND HCC DEVELOPMENT AFTER DAAS FOR CHRONIC HEPATITIS C 108
Noninvasive Assessment of Portal Hypertension in Advanced Chronic Liver Disease: An Update 108
Systemic fungemia and hepatic localizations of Fusarium solani in a liver transplanted patient: An emerging fungal agent. 108
Efficacy of ursodeoxycholic acid administration on clinical manifestations of gallstones and gastrointestinal motility 107
Pattern of macrovascular invasion in hepatocellular carcinoma 106
Long-term leukocyte natural α-interferon and ribavirin treatment in hepatitis C virus recurrence after liver transplantation. 105
Indocyanine green as a predictor of clinically significant portal hypertension in a prospective cohort study of patients with chronic liver disease 105
Interleukin 28 polymorphisms and hepatocellular carcinoma development after direct acting antiviral therapy for chronihepatitis c 105
Severe hypernatremia as a predictor of mortality after percutaneous endoscopic gastrostomy (PEG) placement 105
Hypertransaminasemia and pregnancy outcome. 103
Extracorporeal shock wave lithotripsy for difficult common bile duct stones: a comparison between 2 different lithotripters in a large cohort of patients. 102
Mathematical model predicting high hepatocyte proliferation index and risk of HCC in patients with HCV related cirrhosis: a proposal for clinical validation 102
Superior efficacy of twice a week administration of peginterferon alpha-2b plus ribavirin in obtaining SVR in HCV genotype 1 100
Hepatocellular carcinoma prevention: a worldwide emergence between the opulence of developed countries and the economic constraints of developing nations 100
Hepatobiliary phospholipid transporter ABCB4, MDR3 gene variants in a large cohort of Italian women with intrahepatic cholestasis of pregnancy 100
Chemiluminescence measurement of autotaxin activity in human serum 100
MRP2 is upregulated by UDCA in cholestasis of pregnancy. 100
Severe acute autoimmune hepatitis after natalizumab treatment. 100
Indocyanine Green 15-min Retention test (ICG-r15) as a predictor of clinical decompensation in patients with compensated liver cirrhosis. 99
Indocyanine green clearance as a marker of decompensation and clinically significant portal hypertension in patients with liver cirrhosis. 99
High dose lamivudine in HBV-related cirrhotic patients with unsatisfactory response after adefovir add-on 98
Indocyanine green as a predictor of clinically significant portal hypertension in a prospective cohort study of patients with chronic liver disease 98
Nausea e Vomito 97
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs 97
Effects of UDCA on the foetus-maternal circulation of bilirubin in cholestasis of pregnancy 96
A nomogram-based prognostic model for advanced hepatocellular carcinoma patients treated with sorafenib: A multicenter study 95
Indocyanine green retention test as a non-invasive marker of portal hypertension and esophageal varices in compensated liver cirrhosis. 94
Indocyanine green clearance as a marker of decompensation and clinically significant portal hypertension in patients with liver cirrhosis 94
The foetal-maternal circulation of bile acids and bilirubin: effects of cholestasis and UDCA administration. 93
Genetic polymorphisms of PPAR-alpha: allele frequency in gallstone patients. 93
Indocyanine green clearance (ICG) as a predictor of 2-years clinical decompensation and mortality in patients with compensated liver cirrhosis 93
Two cases of severe autoimmune manifestations following virological response to peginterferon alpha- 2b + ribavirin in liver transplanted patients with recurrence of chronic hepatitis C 92
Pneumatosis Cystoides Intestinalis 92
Indocyanine green as a predictor of clinically significant portal hypertension in a prospective cohort study of patients with chronic liver disease. 92
Fatty liver in pregnancy: a narrative review of two distinct conditions 92
Transjugular intrahepatic portosystemic shunt placement for refractory ascites: a single-centre experience 91
HIGH FREE AND GLYCOCONJUGATED AND LOW TAUROCONJUGATED BA LEVELS IN SERUM ARE THE MIRROR OF INTESTINAL EVENTS AND HEPATIC UPTAKE 91
Indocyanine Green Clearance (ICG) as a predictor of clinical decompensation and mortality in patients with compensated liver cirrhosis 91
Approaches to the Diagnosis of Portal Hypertension: Non-Invasive or Invasive Tests? 91
The pharmacological management of intrahepatic cholestasis of pregnancy. 90
Malattie colestatiche del fegato. Rapporti tra fegato e gravidanza. In: Cirrosi epatica: epidemiologia, diagnosi e terapia. 90
Spleen stiffness measurement predicts the development of primary hepatocellular carcinoma better than hepatic venous pressure gradient 89
Ittero e Colestasi 88
The foetal-maternal circulation of bile acids and bilirubin: effects of cholestasis and UDCA administration. 88
Efficacia del beclometasone dipropionato in un caso di colite plasmacellulare. 87
Effects of UDCA on the foetus-maternal circulation of bilirubin in cholestasis of pregnancy 86
UDCA UP-REGULATES HUMAN PLACENTAL BCRP EXPRESSION: PRELIMINARY RESULTS 86
Insulin resistance in viral hepatitis B and C and non virus related chronic hepatitis 85
Liver transplantation for cholestatic liver diseases: a single center experience 84
Placental MRP2 is upregulated by UDCA in cholestasis of pregnancy. 84
Reply 84
ESWL for difficult bile duct stones: a 15-year single centre experience. 84
Indocyanine green clearance as a marker of decompensation and clinically significant portal hypertension in patients with liver cirrhosis. 84
UDCA UP-REGULATES HUMAN PLACENTAL OATP-A EXPRESSION IN INTRAHEPATIC CHOLESTASIS OF PREGNANCY 84
Totale 11.726
Salva come PNG Salva come JPEG
Categoria #
all - tutte 44.647
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 44.647
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.879 0 0 0 0 0 323 368 381 357 179 96 175
2020/20211.737 331 110 45 54 49 59 52 132 194 78 87 546
2021/20223.293 222 101 160 188 248 147 83 189 137 174 1.190 454
2022/20233.135 348 434 172 387 214 239 114 161 529 98 241 198
2023/20241.036 68 148 55 120 94 228 41 69 63 63 40 47
2024/20252.148 167 618 379 226 613 145 0 0 0 0 0 0
Totale 15.574